Phase 1 study combining elotuzumab with autologous stem cell transplant and lenalidomide for multiple myeloma.

ABSTRACT:

Background

Autologous stem cell transplantation (ASCT) after induction therapy improves disease-free survival for patients with multiple myeloma (MM). While the goal of ASCT is to render a minimal disease state, it is also associated with eradication of immunosuppressive cells, and we hypothesize that early introduction of immunotherapy post-ASCT may provide a window of opportunity to boost treatment efficacy.

Methods

We conducted a phase 1 clinical trial to investigate the application of autologous lymphocyte infusion and anti-SLAMF7 monoclonal antibody, elotuzumab, after ASCT in patients with newly diagnosed MM previously treated with induction therapy. In addition to CD34+ stem cells, peripheral blood mononuclear cells were harvested prior to transplant and infused on day

SUBMITTER: Coffey DG 

PROVIDER: S-EPMC11029259 | biostudies-literature | 2024 Apr

REPOSITORIES: biostudies-literature